Receptor-binding and pharmacokinetic properties of dopaminergic agonists.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacology and receptor-binding mechanisms without systematic methodology.
PubMed 18691132 · doi:10.2174/156802608785161457
What was done
The authors conducted a narrative review evaluating the relationship between receptor-binding profiles, pharmacokinetics, and clinical outcomes of ergot and non-ergot dopamine agonists used in Parkinson's disease and restless legs syndrome. Receptor targets analyzed included dopamine subreceptors (D1 through D4), serotonin receptors (5-HT1A, 5-HT1B, 5-HT2B), alpha-2 adrenergic receptors, and cytochrome P450 interactions.
What was found
The abstract reports no quantitative values or statistical comparisons. Qualitatively, it states that ergot and non-ergot agonists show similar efficacy for Parkinson's disease motor symptoms, but ergots (except bromocriptine) stimulate D1 receptors, increasing dyskinesia. Ergot 8beta-aminoergolines (cabergoline, pergolide) and 5-HT2B agonism are associated with valvular heart disease and fibrosis. Monotherapy with the selective D2 agonist sumanirole was less effective than the D2-like agonist ropinirole, though both showed equal efficacy when added to L-dopa. D3 stimulation was noted as potentially beneficial for mood and neuroprotection, while 5-HT1A agonism and alpha-2 adrenergic antagonism may help reduce dyskinesia.
Why it matters
This paper synthesizes receptor-binding pharmacology to explain why non-ergot D2/D3 agonists offer a superior safety profile over 5-HT2B-activating ergot derivatives in treating movement disorders.
Limits
The abstract describes a narrative review without systematic search methods, study quality appraisal, or quantitative data. Specific human sample sizes, comparative effect sizes, and trial characteristics are omitted.
Cited by
- supports Ropinirole acts as a direct agonist at dopamine D2 and D3 receptors, in contrast to levodopa, which acts as a biochemical precursor for dopamine synthesis.